CAMK2G and Parkinson disease: Concurrently, NMDA receptors, Cav1.3, p-CaMKII (Thr286), and Arc, which were elevated in the PD group and contributed to hyperactivation and excitotoxicity, were reduced in the PD + Ex group (Chen et al., 2017; Garcia et al., 2010).